{"id":"W4408338425","doi":"10.1111/1346-8138.17685","title":"Deucravacitinib in plaque psoriasis: Safety and efficacy through 3 years in Japanese patients in the phase 3 <scp>POETYK PSO</scp> ‐1, <scp>PSO</scp> ‐4, and <scp>LTE</scp> trials","year":2025,"lang":"en","type":"article","venue":"The Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Adverse effect; Placebo; Clinical trial; Psoriasis Area and Severity Index; Psoriasis; Internal medicine; Incidence (geometry); Dermatology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001415084,0.0003286247,0.001259707,0.0001988236,0.0005308856,0.0005855695,0.0002242906,0.0004146172,0.0005493666],"category_scores_gemma":[0.0005928441,0.0001938376,0.0008525167,0.0003739296,0.0002558893,0.0004344069,0.0002201636,0.000981653,0.0001533555],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005419696,"about_ca_system_score_gemma":0.0007347195,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00289693,"about_ca_topic_score_gemma":0.007520166,"domain_scores_codex":[0.999668,0.00009135751,0.00003310202,0.00006831147,0.0000590899,0.00008015874],"domain_scores_gemma":[0.9995828,0.00004132407,0.0001110269,0.00003428687,0.00007267758,0.0001578003],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2481304,0.0131425,0.1558153,0.001945656,0.003845363,0.0006798914,0.001539633,0.003881248,0.0774027,0.0003344899,0.005930559,0.4873524],"study_design_scores_gemma":[0.06048197,0.1870029,0.715461,0.0001862008,0.00566286,0.00126434,0.0004554688,0.00417684,0.01198545,0.0004100707,0.01277739,0.0001355588],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9940535,0.004538112,0.0001326155,0.00009450415,0.0000145273,0.0001062101,0.0002291163,0.00001872831,0.0008126046],"genre_scores_gemma":[0.9969034,0.001662746,0.000201856,0.0001783042,0.00002197512,0.00008173349,0.0004795245,0.000004753179,0.0004655693],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00289693,"threshold_uncertainty_score":0.00748378,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02221781675743524,"score_gpt":0.2900349899425235,"score_spread":0.2678171731850883,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}